Precision BioSciences
DTIL
50 hedge funds and large institutions have $357M invested in Precision BioSciences in 2019 Q1 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.35% more ownership
Funds ownership: 0% → 1.35% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
+$75.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$32.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$21.2M |
| 5 |
CI
Cowen Inc
New York
|
+$17.8M |
Top Sellers
DTIL Hedge Fund Activity: Q1 2019 in Review
50 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q1 2019, worth a combined $357M.
Buyers outnumbered sellers: 50 funds opened new DTIL positions and 0 closed out — a net gain of 50 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was venBio Partners, opening a new position worth an estimated $75.5M.
- 50 institutional investors held Precision BioSciences (DTIL) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $357M of Precision BioSciences stock for Q1 2019.
- 50 funds opened new Precision BioSciences positions in Q1 2019 and 0 closed out, a net change of +50 holders.
- The largest Precision BioSciences buyer in Q1 2019 was venBio Partners, an estimated $75.5M added.
Based on aggregated 13F filings for Q1 2019.